

Marc Pfister

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8424602/marc-pfister-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

130
papers

3,131
citations

28
h-index

52
g-index

146
ext. papers

3,631
ext. citations

4.2
avg, IF

5.16
L-index

#	Paper	IF	Citations
130	Pharmacometric Analysis of Intranasal and Intravenous Nalbuphine to Optimize Pain Management in Infants.. <i>Frontiers in Pediatrics</i> , 2022 , 10, 837492	3.4	0
129	Population Pharmacokinetics and Exposure-Response Analysis of Tribendimidine To Improve Treatment for Children with Hookworm Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2021 , 65,	5.9	1
128	Pharmacometric Analysis of Tribendimidine Monotherapy and Combination Therapies To Achieve High Cure Rates in Patients with Hookworm Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2021 , 65,	5.9	2
127	Hemodialysis (HD) dose and ultrafiltration rate are associated with survival in pediatric and adolescent patients on chronic HD-a large observational study with follow-up to young adult age. <i>Pediatric Nephrology</i> , 2021 , 36, 2421-2432	3.2	1
126	Biologic disease modifying antirheumatic drugs and Janus kinase inhibitors in paediatric rheumatology - what we know and what we do not know from randomized controlled trials. <i>Pediatric Rheumatology</i> , 2021 , 19, 46	3.5	2
125	Serum Creatinine and Serum Cystatin C are Both Relevant Renal Markers to Estimate Vancomycin Clearance in Critically Ill Neonates. <i>Frontiers in Pharmacology</i> , 2021 , 12, 634686	5.6	1
124	Modeling of levothyroxine in newborns and infants with congenital hypothyroidism: challenges and opportunities of a rare disease multi-center study. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2021 , 48, 711-723	2.7	1
123	Identifying key predictors of mortality in young patients on chronic haemodialysis-a machine learning approach. <i>Nephrology Dialysis Transplantation</i> , 2021 , 36, 519-528	4.3	5
122	Characterizing dynamics of serum creatinine and creatinine clearance in extremely low birth weight neonates during the first 6 weeks of life. <i>Pediatric Nephrology</i> , 2021 , 36, 649-659	3.2	7
121	The rhythm of a preterm neonate's life: ultradian oscillations of heart rate, body temperature and sleep cycles. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2021 , 48, 401-410	2.7	0
120	OptiDose: Computing the Individualized Optimal Drug Dosing Regimen Using Optimal Control. <i>Journal of Optimization Theory and Applications</i> , 2021 , 189, 46-65	1.6	2
119	High Acceptability of an Orally Dispersible Tablet Formulation by Children. <i>Children</i> , 2021 , 8,	2.8	3
118	Characterization of the Population Pharmacokinetics of Moxidectin in Adults Infected with Strongyloides Stercoralis: Support for a Fixed-Dose Treatment Regimen. <i>Clinical Pharmacokinetics</i> , 2021 , 1	6.2	1
117	Pharmacometric analysis linking immunoglobulin exposure to clinical efficacy outcomes in chronic inflammatory demyelinating polyneuropathy. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021 , 10, 839-850	4.5	1
116	Infliximab Treatment Does Not Lead to Full TNF- α Inhibition: A Target-Mediated Drug Disposition Model. <i>Clinical Pharmacokinetics</i> , 2021 , 1	6.2	1
115	Optimizing moxidectin dosing for Strongyloides stercoralis infections: Insights from pharmacometric modeling. <i>Clinical and Translational Science</i> , 2021 ,	4.9	1
114	Understanding the Effects of Kidney Disease and Dialysis Treatment on Pharmacotherapy in Children. <i>Handbook of Experimental Pharmacology</i> , 2020 , 261, 209-229	3.2	

113	Clinical Pharmacology and Pharmacometrics to Better Understand Physiological Changes During Pregnancy and Neonatal Life. <i>Handbook of Experimental Pharmacology</i> , 2020 , 261, 325-337	3.2	6
112	Caffeine preserves quiet sleep in preterm neonates. <i>Pharmacology Research and Perspectives</i> , 2020 , 8, e00596	3.1	5
111	Intensive Hemodiafiltration Successfully Removes Ganciclovir Overdose and Largely Exceeds Reported Elimination During Hemodialysis-A Case Report and Review of the Literature. <i>Frontiers in Pharmacology</i> , 2020 , 11, 882	5.6	1
110	Integration of Placental Transfer in a Fetal-Maternal Physiologically Based Pharmacokinetic Model to Characterize Acetaminophen Exposure and Metabolic Clearance in the Fetus. <i>Clinical Pharmacokinetics</i> , 2020 , 59, 911-925	6.2	18
109	Pharmacometrics and Machine Learning Partner to Advance Clinical Data Analysis. <i>Clinical Pharmacology and Therapeutics</i> , 2020 , 107, 926-933	6.1	19
108	Age appropriate reference intervals for eight kidney function and injury markers in infants, children and adolescents. <i>Clinical Chemistry and Laboratory Medicine</i> , 2020 , 59, 373-382	5.9	4
107	MON-102 Serum Concentrations of FT4 and TSH in the First Six Months of L-Thyroxine Treatment in Infants with Congenital Hypothyroidism: Target Attainment Rates Should Be Improved. <i>Journal of the Endocrine Society</i> , 2020 , 4,	0.4	78
106	Understanding Urea Kinetic Factors That Enhance Personalized Hemodialysis Prescription in Children. <i>ASAIO Journal</i> , 2020 , 66, 115-123	3.6	4
105	Comparison of Blood Pressure and Kidney Markers between Adolescent Former Preterm Infants and Term Controls. <i>Children</i> , 2020 , 7,	2.8	3
104	Pharmacometric modeling to explore 4F-PCC dosing strategies for VKA reversal in patients with INR below 2. <i>Blood Advances</i> , 2020 , 4, 4208-4216	7.8	3
103	Amoxicillin Dosing Regimens for the Treatment of Neonatal Sepsis: Balancing Efficacy and Neurotoxicity. <i>Neonatology</i> , 2020 , 117, 619-627	4	4
102	Copeptin Kinetics and Its Relationship to Osmolality During Rehydration for Diabetic Ketoacidosis in Children. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	2
101	Optimisation of vancomycin exposure in neonates based on the best level of evidence. <i>Pharmacological Research</i> , 2020 , 154, 104278	10.2	10
100	Physiologically Based Pharmacokinetic Modeling to Characterize Acetaminophen Pharmacokinetics and N-Acetyl-p-Benzoquinone Imine (NAPQI) Formation in Non-Pregnant and Pregnant Women. <i>Clinical Pharmacokinetics</i> , 2020 , 59, 97-110	6.2	24
99	Creatinine Trends to Detect Ibuprofen-Related Maturation Adverse Drug Events in Neonatal Life: A Simulation Study for the ELBW Newborn. <i>Frontiers in Pharmacology</i> , 2020 , 11, 610294	5.6	0
98	Ivermectin Dosing Strategy to Achieve Equivalent Exposure Coverage in Children and Adults. <i>Clinical Pharmacology and Therapeutics</i> , 2019 , 106, 661-667	6.1	6
97	Methadone dosing strategies in preterm neonates can be simplified. <i>British Journal of Clinical Pharmacology</i> , 2019 , 85, 1348-1356	3.8	5
96	Enhanced early prediction of clinically relevant neonatal hyperbilirubinemia with machine learning. <i>Pediatric Research</i> , 2019 , 86, 122-127	3.2	19

95	Ultrafiltration rates in children on chronic hemodialysis routinely exceed weight based adult limit. <i>Hemodialysis International</i> , 2019 , 23, 126-128	1.7	4
94	Characterization of Maternal and Neonatal Pharmacokinetic Behavior of Ceftazidime. <i>Journal of Clinical Pharmacology</i> , 2019 , 59, 74-82	2.9	4
93	Dose evaluation of intravenous metamizole (dipyrone) in infants and children: a prospective population pharmacokinetic study. <i>European Journal of Clinical Pharmacology</i> , 2019 , 75, 1491-1502	2.8	4
92	Age-Dependent Changes of Kidney Injury Biomarkers in Pediatrics. <i>Journal of Clinical Pharmacology</i> , 2019 , 59 Suppl 1, S21-S32	2.9	4
91	Personalized weight change prediction in the first week of life. <i>Clinical Nutrition</i> , 2019 , 38, 689-696	5.9	5
90	Quantitative Analysis of Gentamicin Exposure in Neonates and Infants Calls into Question Its Current Dosing Recommendations. <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9	19
89	Age- and weight-based differences in haemodialysis prescription and delivery in children, adolescents and young adults. <i>Nephrology Dialysis Transplantation</i> , 2018 , 33, 1649-1660	4.3	7
88	Neurofilament as Neuronal Injury Blood Marker in Preeclampsia. <i>Hypertension</i> , 2018 , 71, 1178-1184	8.5	19
87	Physiologically Based Pharmacokinetic Modeling in Pregnancy: A Systematic Review of Published Models. <i>Clinical Pharmacology and Therapeutics</i> , 2018 , 104, 1110-1124	6.1	40
86	Release and Decay Kinetics of Copeptin vs AVP in Response to Osmotic Alterations in Healthy Volunteers. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018 , 103, 505-513	5.6	47
85	Key Components for Antibiotic Dose Optimization of Sepsis in Neonates and Infants. <i>Frontiers in Pediatrics</i> , 2018 , 6, 325	3.4	15
84	Exploratory Literature Meta-Analysis to Characterize the Relationship Between Early and Longer Term Body Weight Loss for Antiobesity Compounds. <i>Journal of Clinical Pharmacology</i> , 2017 , 57, 52-63	2.9	3
83	Facilitate Treatment Adjustment After Overdosing: Another Step Toward 21st-Century Medicine. <i>Journal of Clinical Pharmacology</i> , 2017 , 57, 704-711	2.9	1
82	Disease Progression Modeling to Evaluate the Effects of Enzyme Replacement Therapy on Kidney Function in Adult Patients with the Classic Phenotype of Fabry Disease. <i>Kidney and Blood Pressure Research</i> , 2017 , 42, 1-15	3.1	8
81	Guidance to develop individual dose recommendations for patients on chronic hemodialysis. <i>Expert Review of Clinical Pharmacology</i> , 2017 , 10, 737-752	3.8	7
80	Validity of mobile electronic data capture in clinical studies: a pilot study in a pediatric population. <i>BMC Medical Research Methodology</i> , 2017 , 17, 163	4.7	8
79	Characterizing the dynamic interaction among gastric emptying, glucose absorption, and glycemic control in nondiabetic obese adults. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2017 , 312, R314-R323	3.2	3
78	Caffeine Citrate Dosing Adjustments to Assure Stable Caffeine Concentrations in Preterm Neonates. <i>Journal of Pediatrics</i> , 2017 , 191, 50-56.e1	3.6	19

77	Pharmacometrics-based decision tools facilitate mHealth implementation. <i>Expert Review of Clinical Pharmacology</i> , 2017 , 10, 39-46	3.8	4
76	A SYSTEMS PHARMACOLOGY MODEL TO EXPLAIN DEVELOPMENTAL DIFFERENCES IN SENSITIVITY TO DRUG-INDUCED QT PROLONGATION. <i>Archives of Disease in Childhood</i> , 2016 , 101, e1.17-e1	2.2	
75	Characterizing and Forecasting Individual Weight Changes in Term Neonates. <i>Journal of Pediatrics</i> , 2016 , 173, 101-107.e10	3.6	11
74	Quantitative clinical pharmacology practice for optimal use of antibiotics during the neonatal period. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016 , 12, 367-75	5.5	12
73	NOVEL APP FOR SMARTPHONES AND TABLETS TO OPTIMIZE AND STANDARDIZE DRUG PRESCRIPTIONS IN NEONATES. <i>Archives of Disease in Childhood</i> , 2016 , 101, e1.19-e1	2.2	
72	SP735BODY-WEIGHT DEPENDENCY OF UREA KINETIC PARAMETERS IN ADOLESCENT HEMODIALYSIS PATIENTS. <i>Nephrology Dialysis Transplantation</i> , 2016 , 31, i339-i340	4.3	2
71	Therapeutic Drug Monitoring for Anti-infective Agents in Pediatrics: The Way Forward. <i>Pediatric Infectious Disease Journal</i> , 2016 , 35, 570-2	3.4	6
70	Causes and Consequences of Variability in Drug Transporter Activity in Pediatric Drug Therapy. <i>Journal of Clinical Pharmacology</i> , 2016 , 56 Suppl 7, S173-92	2.9	14
69	Pharmacometric Approaches to Personalize Use of Primarily Renally Eliminated Antibiotics in Preterm and Term Neonates. <i>Journal of Clinical Pharmacology</i> , 2016 , 56, 909-35	2.9	48
68	Effect of Kidney Function on Drug Kinetics and Dosing in Neonates, Infants, and Children. <i>Clinical Pharmacokinetics</i> , 2015 , 54, 1183-204	6.2	70
67	Model-based exposure-response analysis of apixaban to quantify bleeding risk in special populations of subjects undergoing orthopedic surgery. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2014 , 3, e136	4.5	30
66	Modeling and simulation for medical product development and evaluation: highlights from the FDA-C-Path-ISOP 2013 workshop. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2014 , 41, 545-52	2.7	16
65	Enhancing Patient Flexibility of Subcutaneous Immunoglobulin G Dosing: Pharmacokinetic Outcomes of Various Maintenance and Loading Regimens in the Treatment of Primary Immunodeficiency. <i>Biologics in Therapy</i> , 2014 , 4, 41-55		22
64	Subcutaneous immunoglobulin loading regimens for previously untreated patients with primary antibody deficiency. <i>Clinical and Experimental Immunology</i> , 2014 , 178 Suppl 1, 146-8	6.2	6
63	Pharmacometrics in Chronic Kidney Disease. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2014 , 109-137	0.5	1
62	The American Conference on Pharmacometrics 2013. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2013 , 40, 1-1	2.7	
61	The International Society of Pharmacometrics. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2013 , 40, 3-4	2.7	2
60	The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus. <i>British Journal of Clinical Pharmacology</i> , 2013 , 76, 432-44	3.8	82

59	A Nonlinear Mixed Effects Pharmacokinetic Model for Dapagliflozin and Dapagliflozin 3-O-glucuronide in Renal or Hepatic Impairment. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2013 , 2, e42	4.5	19
58	Pharmacokinetic modeling and simulation of biweekly subcutaneous immunoglobulin dosing in primary immunodeficiency. <i>Postgraduate Medicine</i> , 2013 , 125, 53-61	3.7	27
57	Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes. <i>Diabetes Care</i> , 2013 , 36, 3169-76	14.6	193
56	Pharmacometric Approaches to Guide Dose Selection of the Novel GPR40 Agonist TAK-875 in Subjects With Type 2 Diabetes Mellitus. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2013 , 2, e22	4.5	11
55	Affiliation between the American Society of Pharmacometrics and the Journal of Pharmacokinetics and Pharmacodynamics. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2012 , 39, 3	2.7	1
54	A pharmacometric approach to quantify the impact of chronic kidney disease and hemodialysis on systemic drug exposure: application to saxagliptin. <i>Journal of Clinical Pharmacology</i> , 2012 , 52, 126S-33S	2.9	13
53	Novel dialysis modalities: do we need new metrics to optimize treatment?. <i>Journal of Clinical Pharmacology</i> , 2012 , 52, 72S-8S	2.9	4
52	Optimizing drug development and use in patients with kidney disease: opportunities, innovations, and challenges. <i>Journal of Clinical Pharmacology</i> , 2012 , 52, 4S-6S	2.9	4
51	Design, conduct, analysis, and interpretation of clinical studies in patients with impaired kidney function. <i>Journal of Clinical Pharmacology</i> , 2012 , 52, 109S-18S	2.9	14
50	Time-varying belatacept exposure and its relationship to efficacy/safety responses in kidney-transplant recipients. <i>Clinical Pharmacology and Therapeutics</i> , 2012 , 92, 251-7	6.1	25
49	Pooled model-based approach to compare the pharmacokinetics of entecavir between Japanese and non-Japanese chronic hepatitis B patients. <i>Diagnostic Microbiology and Infectious Disease</i> , 2011 , 70, 91-100	2.9	2
48	Quantifying the impact of nonadherence patterns on exposure to oral immunosuppressants. <i>Therapeutics and Clinical Risk Management</i> , 2011 , 7, 149-56	2.9	14
47	Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects. <i>Diabetes, Obesity and Metabolism</i> , 2011 , 13, 47-54	6.7	65
46	Effect of a high-fat meal on the pharmacokinetics of dapagliflozin, a selective SGLT2 inhibitor, in healthy subjects. <i>Diabetes, Obesity and Metabolism</i> , 2011 , 13, 770-3	6.7	30
45	Inhibition of SGLT2: a novel strategy for treatment of type 2 diabetes mellitus. <i>Clinical Pharmacology and Therapeutics</i> , 2011 , 89, 621-5	6.1	20
44	Influence of hepatic impairment on the pharmacokinetics and safety profile of dapagliflozin: an open-label, parallel-group, single-dose study. <i>Clinical Therapeutics</i> , 2011 , 33, 1798-808	3.5	61
43	Model-based meta-analysis for comparative efficacy and safety: application in drug development and beyond. <i>Clinical Pharmacology and Therapeutics</i> , 2011 , 90, 766-9	6.1	63
42	Optimizing drug development and use in patients with kidney disease. <i>Journal of Clinical Pharmacology</i> , 2011 , 51, 628-30	2.9	2

41	Model-based approach for optimization of atazanavir dose recommendations for HIV-infected pediatric patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2011 , 55, 5746-52	5.9	9
40	Quantification of apixaban [®] therapeutic utility in prevention of venous thromboembolism: selection of phase III trial dose. <i>Clinical Pharmacology and Therapeutics</i> , 2010 , 88, 375-82	6.1	68
39	Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight. <i>Diabetes, Obesity and Metabolism</i> , 2010 , 12, 510-6	6.7	131
38	Model-based drug development survey finds pharmacometrics impacting decision making in the pharmaceutical industry. <i>Journal of Clinical Pharmacology</i> , 2010 , 50, 20S-30S	2.9	35
37	ACoP: the tools, carpenters, and architects building the discipline of pharmacometrics. <i>Journal of Clinical Pharmacology</i> , 2010 , 50, 7S-8S	2.9	
36	Model-based drug development: strengths, weaknesses, opportunities, and threats for broad application of pharmacometrics in drug development. <i>Journal of Clinical Pharmacology</i> , 2010 , 50, 31S-46S	2.9	18
35	Synergy between scientific advancement and technological innovation, illustrated by a mechanism-based model characterizing sodium-glucose cotransporter-2 inhibition. <i>Journal of Clinical Pharmacology</i> , 2010 , 50, 113S-120S	2.9	7
34	The current role of model-based drug development. <i>Expert Opinion on Drug Discovery</i> , 2010 , 5, 311-21	6.2	23
33	Fostering culture and optimizing organizational structure for implementing model-based drug development. <i>Journal of Clinical Pharmacology</i> , 2010 , 50, 146S-150S	2.9	6
32	Application of Individualized Bayesian Urea Kinetic Modeling to pediatric hemodialysis. <i>ASAIO Journal</i> , 2010 , 56, 246-53	3.6	8
31	Model-based approach to characterize efavirenz autoinduction and concurrent enzyme induction with carbamazepine. <i>Antimicrobial Agents and Chemotherapy</i> , 2009 , 53, 2346-53	5.9	44
30	Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. <i>Clinical Pharmacology and Therapeutics</i> , 2009 , 85, 513-9	6.1	294
29	Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. <i>Clinical Pharmacology and Therapeutics</i> , 2009 , 85, 520-6	6.1	256
28	Importance of characterizing determinants of variability in exposure: application to dasatinib in subjects with chronic myeloid leukemia. <i>Journal of Clinical Pharmacology</i> , 2008 , 48, 1254-69	2.9	31
27	Lack of an effect of human immunodeficiency virus coinfection on the pharmacokinetics of entecavir in hepatitis B virus-infected patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2008 , 52, 2836-41	5.9	11
26	Concepts and challenges in quantitative pharmacology and model-based drug development. <i>AAPS Journal</i> , 2008 , 10, 552-9	3.7	76
25	Modeling and simulation of abatacept exposure and interleukin-6 response in support of recommended doses for rheumatoid arthritis. <i>Journal of Clinical Pharmacology</i> , 2007 , 47, 1408-20	2.9	30
24	Pharmacodynamic analysis of the microbiological efficacy of telithromycin in patients with community-acquired pneumonia. <i>Clinical Pharmacokinetics</i> , 2005 , 44, 317-29	6.2	8

23	Application and impact of population pharmacokinetics in the assessment of antiretroviral pharmacotherapy. <i>Clinical Pharmacokinetics</i> , 2005 , 44, 591-625	6.2	20
22	Model-based covariate pharmacokinetic analysis and lack of cortisol suppression by the new inhaled corticosteroid ciclesonide using a novel cortisol release model. <i>American Journal of Therapeutics</i> , 2005 , 12, 385-97	1	36
21	Modeling and simulation of adherence: approaches and applications in therapeutics. <i>AAPS Journal</i> , 2005 , 7, E390-407	3.7	30
20	Daptomycin is highly efficacious against penicillin-resistant and penicillin- and quinolone-resistant pneumococci in experimental meningitis. <i>Antimicrobial Agents and Chemotherapy</i> , 2004 , 48, 3928-33	5.9	83
19	A new Bayesian method to forecast and fine tune individual hemodialysis dose. <i>Hemodialysis International</i> , 2004 , 8, 244-56	1.7	7
18	Optimizing dose selection with modeling and simulation: application to the vasopeptidase inhibitor M100240. <i>Journal of Clinical Pharmacology</i> , 2004 , 44, 621-31	2.9	11
17	Modeling of transfer kinetics at the serum-cerebrospinal fluid barrier in rabbits with experimental meningitis: application to grepafloxacin. <i>Antimicrobial Agents and Chemotherapy</i> , 2003 , 47, 138-43	5.9	9
16	Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group Study 398. <i>Antimicrobial Agents and Chemotherapy</i> , 2003 , 47, 130-7	5.9	114
15	Activities of ertapenem, a new long-acting carbapenem, against penicillin-sensitive or -resistant pneumococci in experimental meningitis. <i>Antimicrobial Agents and Chemotherapy</i> , 2003 , 47, 1943-7	5.9	25
14	Effect of coadministration of nelfinavir, indinavir, and saquinavir on the pharmacokinetics of amprenavir. <i>Clinical Pharmacology and Therapeutics</i> , 2002 , 72, 133-41	6.1	27
13	Efficacies of BMS 284756 against penicillin-sensitive, penicillin-resistant, and quinolone-resistant pneumococci in experimental meningitis. <i>Antimicrobial Agents and Chemotherapy</i> , 2002 , 46, 184-7	5.9	11
12	Additive antiproteinuric effect of combined ACE inhibition and angiotensin II receptor blockade. <i>Journal of Hypertension</i> , 2002 , 20, 125-30	1.9	89
11	Pharmacokinetic-pharmacodynamic modelling of magnesium plasma concentration and blood pressure in preeclamptic women. <i>Clinical Pharmacokinetics</i> , 2002 , 41, 1105-13	6.2	16
10	Elevated carbohydrate antigen 19-9 (CA 19-9) in patients with Echinococcus infection. <i>Clinical Chemistry and Laboratory Medicine</i> , 2001 , 39, 527-30	5.9	7
9	Proinflammatory effects in experimental mesangial proliferative glomerulonephritis of the immunosuppressive agent SDZ RAD, a rapamycin derivative. <i>Nephron Experimental Nephrology</i> , 2000 , 8, 52-62		45
8	"Kissing balloon technique" for bilateral iliac artery obstruction in retroperitoneal fibrosis. <i>European Journal of Vascular and Endovascular Surgery</i> , 2000 , 20, 394-6	2.3	3
7	Novel dialysis cannulas: are they worth the higher price tag?. <i>American Journal of Kidney Diseases</i> , 2000 , 35, 624-8	7.4	2
6	Ambulatory nocturnal oximetry and sleep questionnaire-based findings in 38 patients with end-stage renal disease. <i>Nephrology Dialysis Transplantation</i> , 1999 , 14, 1496-502	4.3	8

5	Pharmacokinetics and haemodynamics of candesartan cilexetil in hypertensive patients on regular haemodialysis. <i>British Journal of Clinical Pharmacology</i> , 1999 , 47, 645-51	3.8	22
4	Immunodiagnosis of echinococcosis in cancer patients. <i>Clinical Microbiology and Infection</i> , 1999 , 5, 693-697	9.5	14
3	Judgment analysis in clinical nephrology. <i>American Journal of Kidney Diseases</i> , 1999 , 34, 569-75	7.4	12
2	Differential immunodiagnosis between cystic hydatid disease and other cross-reactive pathologies. <i>American Journal of Tropical Medicine and Hygiene</i> , 1999 , 60, 193-8	3.2	89
1	Nitrate induced coronary vasodilatation: differential effects of sublingual application by capsule or spray. <i>Heart</i> , 1998 , 80, 365-9	5.1	14